The significance of this study includes (1) offering hypoglycemic agents a sustainable approach to pharmaceutical development, reducing reliance on chemically synthesized DPP-IV inhibitors, which are a medicine for type-2 diabetes, and (2) identifying the competitive inhibition mode and specific binding sites through molecular docking to gain insights into the mechanism of action of these peptides. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.